SITE008-0160

SITE008 (KOR) › SITE008-0160

SITE008-0160

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2026-03-06

enrolled

AEs

1

Serious

0

Dropout signal

–

Adverse events

1

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-10-31 (study day 43); relationship: NOT RELATED

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.